Welcome to our dedicated page for Clearmind Medici news (Ticker: CMND), a resource for investors and traders seeking the latest updates and insights on Clearmind Medici stock.
Clearmind Medicine Inc. (CMND) is a clinical-stage psychedelic pharmaceutical biotech company focused on developing novel neuroplastogen-derived and psychedelic-derived therapeutics, with a lead program targeting alcohol use disorder (AUD). The Clearmind news feed on Stock Titan highlights company announcements that trace the progress of its clinical pipeline, intellectual property strategy, and exchange listing status.
News items commonly cover key milestones in Clearmind’s FDA-approved Phase I/IIa clinical trial of CMND-100, its proprietary non-hallucinogenic MEAI-based oral candidate for AUD. These updates include cohort enrollment and completion, dosing at new clinical sites such as Yale School of Medicine, Johns Hopkins University, Tel Aviv Sourasky Medical Center, and Hadassah Medical Center, and decisions by the independent Data and Safety Monitoring Board to allow the trial to continue following interim safety reviews.
Investors following CMND news will also see disclosures on peer-reviewed publications discussing MEAI’s pharmacological and receptor interaction profile, as well as articles that compare MEAI with other psychedelics and entactogens in the context of AUD. In addition, Clearmind regularly reports on capital markets developments, such as registered direct offerings, reverse share splits, and notifications from Nasdaq regarding compliance with minimum bid price and stockholders’ equity requirements.
This news page allows readers to track how Clearmind’s clinical-stage activities, patent portfolio expansion, and listing compliance efforts evolve over time. For anyone monitoring CMND stock or the broader field of psychedelic and neuroplastogen-based therapeutics for addiction and mental health, the Clearmind news stream provides a centralized view of the company’s publicly reported developments.
Clearmind Medicine (Nasdaq: CMND) entered a development agreement with Polyrizon to create an intranasal hydrogel formulation of its lead non-hallucinogenic neuroplastogen, MEAI, to enhance bioavailability and support ongoing and future clinical programs for addiction-related and CNS disorders.
The collaboration targets enhanced nasal residence time, targeted CNS delivery, optimized patient usability, and formulation flexibility tailored to MEAI. The transaction is a related-party arrangement and Clearmind is relying on MI61-101 exemptions for valuation and minority approval.
Clearmind (NASDAQ: CMND) announced that its proprietary compound MEAI (5-MeO-AI) was named in newly introduced bipartisan U.S. legislation, the Expanding Veterans’ Access to Emerging Treatments Act of 2026 (H.R. 7091). The bill would direct the VA to create investigational research and extended access programs covering MEAI and other emerging therapies.
If passed, H.R. 7091 aims to support VA-backed clinical trials and extended access protocols for conditions including Alcohol Use Disorder and PTSD, expanding veteran access to innovative treatments.
Clearmind Medicine (Nasdaq: CMND) announced it filed its Annual Report on Form 20-F for the fiscal year ended October 31, 2025 with the U.S. Securities and Exchange Commission on January 20, 2026. The report is available on the SEC website and on Clearmind's Investor Relations website. Shareholders may request free copies by contacting Clearmind's Investor Relations Department via the provided email address. The filing relates to the company's clinical-stage work on neuroplastogen-derived therapeutics.
Clearmind Medicine (Nasdaq: CMND) announced that all patients in the second cohort of its FDA-approved Phase I/IIa trial of CMND-100 for Alcohol Use Disorder have completed treatment per protocol.
The second cohort included 6 patients enrolled across multinational sites including Johns Hopkins University, Tel Aviv Sourasky Medical Center, and Hadassah Medical Center. This milestone follows DSMB approval to continue enrollment and builds on the first cohort’s reported favorable safety profile and preliminary signals of reduced cravings and withdrawal. Topline results from cohort two are expected in the coming months as the study continues to evaluate safety, tolerability, pharmacokinetics, and preliminary efficacy.
Clearmind Medicine (Nasdaq: CMND) announced it has regained compliance with the Nasdaq minimum bid price requirement under Listing Rule 5550(a)(2). Nasdaq confirmed on December 30, 2025 that the company’s common shares closed at $1.00 or greater for 10 consecutive business days from December 15 through December 29, 2025.
The company had previously received a notice of noncompliance dated December 4, 2025 after the closing bid price remained below $1.00 for more than 30 consecutive business days. Nasdaq indicated the matter is now closed.
Clearmind Medicine (Nasdaq: CMND) reviewed 2025 progress, highlighting clinical and intellectual property advances for its lead candidate CMND-100, an oral non-hallucinogenic MEAI-based therapy for Alcohol Use Disorder (AUD).
Key 2025 points: first-in-human dosing and completed enrollment/treatment for cohort 1, completed dosing for cohort 2, DSMB unanimous approval to continue after interim safety review, multinational site activations at Yale, Johns Hopkins and Israeli centers, and multiple international patent filings across neuroplastogen indications.
Clearmind Medicine (Nasdaq: CMND) announced completion of patient enrollment for the second cohort in its FDA-approved Phase I/IIa trial of CMND-100 for Alcohol Use Disorder on Dec. 16, 2025. The six-patient cohort was recruited rapidly across three clinical sites: Johns Hopkins University, Tel Aviv Sourasky Medical Center, and Hadassah Medical Center.
The trial is multinational and will assess safety, tolerability, pharmacokinetics, and preliminary efficacy in moderate-to-severe AUD. Dosing for the second cohort is expected to start shortly, and topline results are anticipated in the coming months. The announcement references encouraging topline safety and preliminary efficacy signals from the first cohort.
Clearmind Medicine (Nasdaq: CMND) announced a peer-reviewed review published Dec 2, 2025 in Current Addiction Reports evaluating its proprietary candidate MEAI (CMND-100) for alcohol use disorder (AUD).
The review, led by experts including Anahita Bassir Nia from Yale, examines MEAI's pharmacology, receptor interactions, preclinical efficacy, and emerging clinical observations, and positions MEAI as a potential AUD treatment with milder subjective effects and lower cardiovascular, neurotoxicity, and abuse potential than MDMA and classic psychedelics. Recreational dosing reported at 1–2 mg/kg orally with positive effects around 4 hours is cited. The review notes no serious adverse events reported by recreational users but highlights there are no published human adverse‑effect studies to date, while receptor data suggest reduced 5-HT2A/2B/2C activity and no 5-HT2B calcium flux agonism.
Clearmind Medicine (Nasdaq: CMND) announced on Dec 12, 2025 that Nasdaq notified the company on Dec 10, 2025 it has regained compliance with Nasdaq Listing Rule 5550(b)(1), the Minimum Stockholders' Equity Rule requiring at least $2,500,000 in stockholders' equity. The notice follows Clearmind's Form 6-K filed Dec 5, 2025. Nasdaq said it will continue to monitor the company's compliance and warned that if Clearmind does not demonstrate compliance at its next periodic report, it may be subject to delisting. The company remains a clinical-stage biotech developing neuroplastogen-derived therapeutics.
Clearmind Medicine (Nasdaq: CMND) will implement a 1-for-40 reverse share split effective December 15, 2025 to regain compliance with the Nasdaq Minimum Bid Price Rule. The board approved the reverse split on November 12, 2025. The reverse split will reduce the number of issued and outstanding common shares from 59,991,852 to 1,499,796, subject to fractional-share treatment.
No fractional common shares will be issued; instead, fractional shares will be rounded up to the nearest whole share. The company said authorized share capital remains unchanged and that outstanding options and warrants will be proportionately adjusted in quantity and per-share exercise price.
FAQ
What is the current stock price of Clearmind Medici (CMND)?
What is the market cap of Clearmind Medici (CMND)?
